UK markets closed

Viridian Therapeutics, Inc. (0K1R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
17.53-0.13 (-0.74%)
At close: 05:38PM GMT

Viridian Therapeutics, Inc.

221 Crescent Street
Suite 401
Waltham, MA 02453
United States
617 272 4600
https://www.viridiantherapeutics.com

Sector(s)
Industry
Full-time employees94

Key executives

NameTitlePayExercisedYear born
Mr. Stephen F. Mahoney J.D., MBACEO, President & DirectorN/AN/A1972
Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Michael R. Bristow M.D., Ph.D.Co-Founder & Member of the Scientific Advisory BoardN/AN/A1945
Dr. Marvin H. Caruthers Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/A1940
Mr. Vahe Bedian Ph.D.Co-Founder & Scientific AdvisorN/AN/AN/A
Mr. Seth HarmonSenior VP of Finance and Accounting, Principal Financial & Accounting OfficerN/AN/AN/A
Mr. Thomas W. Beetham J.D., MBAChief Operating OfficerN/AN/A1970
Ms. Jennifer Tousignant J.D.Chief Legal OfficerN/AN/AN/A
Mr. John A. JordanVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Anthony CasicanoChief Commercial OfficerN/AN/A1977
Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Corporate governance

Viridian Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.